Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations.

Table 3 shows that the clinical-genomic signatures significantly outperformed the clinical signatures as prognostic models in both the training and validation sets, except for the ADC signature in the validation set, which despite having a better performance ( p -value below 0.5) did not reach statistical significance.

also in 111,027 other papers